Anixa Biosciences announces enrollment for Keytruda treatment arm

Anixa Biosciences (ANIX) announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the Company’s breast cancer vaccine with Keytruda, or pembrolizumab. An expansion of the ongoing Phase 1 dose escalation trial of Anixa’s breast cancer vaccine, this treatment arm aims to determine if the vaccine/Keytruda combination increases immune response. Anixa’s breast cancer vaccine is designed to generate T cells that target triple negative breast cancer, or TNBC. Keytruda, a therapy marketed by Merck (MRK), is approved for use with chemotherapy before surgery and then alone after surgery to treat both high-risk early-stage and advanced TNBC. Keytruda is a type of immunotherapy known as a checkpoint inhibitor.